AE 941

Drug Profile

AE 941

Alternative Names: Arthrovas; Neoretna; Neovastat; Psovascar; Shark cartilage extract AE 941

Latest Information Update: 07 Mar 2007

Price : $50

At a glance

  • Originator AEterna Zentaris Inc
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Breast cancer; Multiple myeloma; Non-small cell lung cancer; Osteoarthritis; Prostate cancer; Psoriasis; Renal cancer; Rheumatoid arthritis

Most Recent Events

  • 05 Mar 2007 Discontinued - Phase-III for Non-small cell lung cancer in USA (PO)
  • 05 Mar 2007 Discontinued - Phase-III for Non-small cell lung cancer in Canada (PO)
  • 17 Feb 2006 The US National Cancer Institute has interrupted enrolment in a phase III trial for Non-small cell lung cancer in the USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top